Engflag

Grct

Quick links to important sections

Grct

Grct_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Grct

What is Grct? Definition, Class, and Composition

Property Description
Active Ingredients Cefoperazone and Tazobactam
Form Powder for Injection (Dry Vial)
Pharmacological Class Beta-lactam Antibiotic + Beta-lactamase Inhibitor
Common Purpose Combating bacterial infections
Origin Semisynthetic (for Cefoperazone)

Grct is an anti-bacterial agent classified as a fixed-dose combination product designed to combat bacterial infections by neutralizing bacterial defenses. Its identity is defined by two active ingredients: the antibiotic Cefoperazone and the enzyme inhibitor Tazobactam. This combination is widely recognized in clinical practice for its application when confronting pathogens with established mechanisms of resistance.

The drug belongs to the high-level pharmacological class of Beta-lactam antibiotics because its core component, Cefoperazone, is a semisynthetic third-generation cephalosporin, a class known for its broad activity. The Cefoperazone component functions by inhibiting the synthesis of the bacterial cell wall. The combination is supplied as a sterile Powder for Injection in a dry vial, necessitating Parenteral administration.

General Purpose and the Role of the Combination

The primary general purpose of combining Cefoperazone with Tazobactam is to create a robust formulation that achieves a broad spectrum of bactericidal action against pathogens, even those showing resistance to Cefoperazone alone. This synergistic effect enables the drug to overcome a common bacterial defense mechanism.

The Tazobactam component, acting as a Beta-lactamase inhibitor, works to protect the Cefoperazone from degradation by enzymes that the bacteria use for resistance. This specific formulation is used to address resistant strains more effectively than other similar antibiotic mixtures. By preserving the antibiotic's potency, the combination ensures that Cefoperazone can proceed with its function—interfering with bacterial cell wall synthesis—to deliver antibacterial activity against a wide range of Gram-negative and Gram-positive bacterial infections. Its clinical application is often seen in treating serious infections where resistance is a significant concern.

Regulatory References

  1. WHO Essential Medicines List: Piperacillin + Tazobactam

What side effects are possible with Grct?

Possible side effects and safety information

The general safety profile of Grct (Cefoperazone/Tazobactam) is structured around common adverse reactions typical of beta-lactam antibiotics and specific concerns related to the Cefoperazone component, as documented in official regulatory labeling.

Adverse Reaction Scope

The most common adverse reaction listed in regulatory documents is diarrhea. Other effects classified as uncommon include rash and urticaria (hives). Reactions are formally categorized across several physiological systems:

  • Gastrointestinal Disorders: Diarrhea and the serious, though less frequent, risk of Pseudomembranous Colitis (Clostridium difficile-associated diarrhea/CDAD).
  • Blood and Lymphatic System Disorders: Potential for hemorrhage (bleeding) due to hypoprothrombinemia (coagulopathy), a specific safety concern associated with the Cefoperazone component.
  • Immune System Disorders: The label includes warnings for serious and occasionally fatal hypersensitivity (anaphylactic) reactions.
  • Skin and Subcutaneous Tissue Disorders: Includes the risk of Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety Considerations and Restrictions

Official labeling defines specific safety limitations and population considerations:

  • Special Populations: Dose adjustments may be necessary for individuals with severe hepatic dysfunction due to altered drug clearance. Periodic checking of renal, hepatic, and hematopoietic systems is advised during extended therapy, particularly in infants and neonates.
  • Exposure-Related Patterns: Regulatory documentation notes that CDAD can manifest two months or more after administration has been completed.
  • Safety Restriction: A Disulfiram-like reaction (flushing, rapid heart rate) has been reported when alcohol is consumed during and for several days following treatment; this restriction is explicitly noted in the product's safety information.

These safety facts structure the official risk profile, highlighting specific events that require monitoring beyond the immediate treatment period.

Overdose and Emergency Response

Grct Overdose and when to seek help

The official regulatory documentation on Grct (Cefoperazone/Tazobactam) overdose states that high exposures are expected to primarily produce manifestations that are extensions of the adverse reactions reported with the drug. The documented severe risk involves the Central Nervous System (CNS). High concentrations of the beta-lactam component in the CNS may lead to neurologic effects, including seizures (convulsive or non-convulsive episodes). Such severe clinical presentations indicate a critical scenario requiring specialized medical intervention.

When to Seek Immediate Medical Help

If an overdose is suspected or if severe manifestations such as seizures or other pronounced neurologic effects occur, immediate medical attention must be sought. This action is mandated because the management of overdose is purely symptomatic and supportive; the official labeling confirms that no specific antidote is documented or known for the drug.

Management and Population Considerations

Treatment procedures focus on supporting vital functions and managing the acute clinical presentation. Hemodialysis is an officially described procedural step that may be utilized to enhance the elimination of the drug from the body. This procedure is a specific consideration for managing overdose in patients who have impaired renal function, as their reduced kidney clearance affects the drug's removal from systemic circulation.

Therapeutic Uses of Grct

What Grct Treats: Main Uses and Benefits

Grct (Cefoperazone/Tazobactam) is a combination antibiotic commonly used in situations involving certain distressing symptoms caused by a variety of severe and complicated bacterial infections. It plays a role in assisting with the management of bacterial growth, particularly against organisms that may have developed resistance.

This combination is utilized in a broad range of critical conditions. It is relevant in contexts involving heightened systemic burden, supporting the patient during difficult episodes by easing distress. The medication may assist with addressing symptom clusters that may become intense or disruptive in conditions such as septicemia, severe lower respiratory tract infections, intra-abdominal infections, complicated urinary tract infections, and serious gynecological infections.

“This type of supportive therapy is considered relevant in high-risk clinical settings which involve acute or unstable symptom patterns.”

The combination is often used during phases when symptoms become more noticeable in hospital-acquired infections or in immunocompromised patients. It provides supportive relief when symptoms interfere with routine activities, and plays a role in managing bacterial growth against strains that may be difficult to treat, supporting general well-being during symptomatic phases.

Quick Fact: Support for Symptoms Related to Systemic Imbalance Grct is applied in situations where persistent high fever and severe localized pain are present due to underlying bacterial infection, contributing to easing the overall symptom load.

Regulatory References

  1. FDA Verification Portal for Sulbactam/Cefoperazone

Eligibility and Restrictions for Use

Who can and cannot use Grct?

The eligibility for Grct (Cefoperazone/Tazobactam) is defined by official government labeling based on patient history, age, and existing medical conditions. Adult patients without contraindications are the standard eligible group, with conditional eligibility for the geriatric population.

Category Official Regulatory Statement
Populations for whom use is contraindicated The medicine is strictly forbidden for individuals with a history of severe hypersensitivity or allergic reaction to Cefoperazone, Tazobactam, or any other beta-lactam antibacterial agents, including penicillins.
Condition-specific eligibility rules Use requires caution and monitoring in patients with significant hepatic disease or biliary obstruction due to the component's primary excretion route. Caution is also necessary for those with pre-existing bleeding disorders or a history of colitis.
Age-related eligibility rules Use is not recommended in neonates or preterm infants due to specific safety concerns documented in labeling. Pediatric patients are eligible for certain indications.
Pregnancy and lactation eligibility status The medicine is not recommended during pregnancy or for breastfeeding women, as safety for the fetus or infant has not been conclusively established in regulatory documentation.

The resulting eligibility profile limits use to populations where the medicine's safety and effectiveness are established or can be adequately managed under restricted conditions.

What should I know about interactions with other medicines?

The interaction profile for Grct (Cefoperazone/Tazobactam) is defined by officially documented effects across pharmacodynamic, pharmacokinetic, and substance interactions, requiring specific restrictions.

Timing and Substance Restrictions

The co-administration of Grct with alcohol (ethanol) is subject to a formal restriction due to an established enzyme-mediated interaction, which can result in a disulfiram-like reaction (flushing, sweating, tachycardia). Mandatory avoidance of alcohol is required during treatment and typically for a specified period, such as 72 hours, following the final dose. Certain non-absorbable agents, such as bile acid sequestrants (e.g., Cholestyramine), cause a pharmacokinetic interaction by reducing the absorption of Grct. To prevent reduced systemic exposure, regulatory rules dictate mandatory separation of administration, requiring the sequestrant to be taken at least 1 hour before or 4 to 6 hours after Grct.

Pharmacodynamic and Additive Risk Interactions

The combination of Grct with anticoagulants (e.g., Warfarin, Heparin) carries a documented increased risk of bleeding (hypoprothrombinemia). This interaction is related to interference with Vitamin K-dependent clotting factors. This specific pharmacodynamic risk is officially noted as being heightened in patients with poor nutrition status. Furthermore, the concurrent use of Grct with aminoglycoside antibiotics (e.g., Gentamicin, Amikacin) is associated with an additive risk of nephrotoxicity. For patients with hepatic impairment, the entire interaction profile may be more pronounced due to the Cefoperazone component’s prolonged half-life, a consideration explicitly noted in regulatory documents. The profile’s structure ensures all clinically significant interactions are governed by official label constraints.

Mechanism of Action

How Grct Works

Blockade of Serotonin Receptors (5-HT3)

The drug Grct is a highly selective antagonist that binds to and occupies the 5-HT3 receptors . This molecular action competitively prevents the natural chemical messenger serotonin (5-HT) from accessing the receptor's binding site. As a result of this occupation, the drug inhibits the receptor-linked ion channel from opening and thereby prevents the generation of electrical signaling in the associated nerve cell.

Interruption of the Dual Signaling Pathway

This mechanism involves action at two primary anatomical locations: the peripheral vagal nerve endings in the gastrointestinal tract and the central Chemoreceptor Trigger Zone in the brainstem. By interrupting the signal transmission at both sites, the drug reduces the transmission of neural impulses that carry visceral signals toward the central regulatory center. This targeted interference with 5-HT signaling results in the inhibition of the associated efferent signaling pathway, modifying the reflex response.

Dosage and Administration Information

How Grct is Used: Administration Principles and Official Dosing

Grct (Cefoperazone/Tazobactam) is administered exclusively by the parenteral route, meaning it is given via injection and not taken orally. As a sterile dry powder, the medicine requires reconstitution and dilution with a compatible sterile solution, such as 0.9% Sodium Chloride, before it can be used.

Official Routes and Infusion

The approved methods for administration are primarily Intravenous (IV) infusion or, less commonly, Intramuscular (IM) injection. When administered intravenously, the diluted solution must be infused slowly over a period of 15 to 30 minutes.

Standard Dosing Regimens and Frequency

The dosage is calculated based on the Cefoperazone activity within the combination product. The typical adult dose is in the range of 2 to 4 grams of Cefoperazone activity daily, which is divided and administered in equal portions every 12 hours (Q12h). For severe infections, the daily dose may be increased up to a maximum of 8 grams of Cefoperazone activity.

Population and Organ-Function Adjustments

Specific dosage modifications are required when treating patients with impaired organ function. For individuals with reduced kidney function (renal impairment), the dose must be adjusted to limit exposure to the beta-lactamase inhibitor component. Patients on hemodialysis should receive their dose after the dialysis session is completed. Similarly, if severe hepatic dysfunction is present, particularly with concurrent renal issues, the Cefoperazone dose should not exceed 2 grams per day without close serum monitoring. Dosing for the pediatric population is determined by body weight (mg/kg/day), with scheduled administration every 6 to 12 hours. The duration of use is defined as a course of therapy, typically lasting until the infection is resolved.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Grct

Evidence for Use in Severe and Complicated Bacterial Infections

Research on the combination of Cefoperazone and Tazobactam has been conducted primarily through pharmacological studies and reviews of its application in clinical practice. This evidence has explored the combination in the context of bacterial infections, especially in situations where bacteria may have developed ways to resist typical antibiotics. These studies monitored outcomes related to physiological strain and examined its activity against specific resistance mechanisms. Findings indicate that the combination was observed in studies examining patient experiences related to systemic or functional imbalance associated with resistant organisms.

However, the evidence is often based on the general application of this class of combination antibiotics. While the core research helps contextualize how the drug is intended to function, specific, large-scale studies directly focused on long-term patient outcomes for the Cefoperazone/Tazobactam formulation in this broad category are not broadly characterized. The certainty remains low for certain aspects, as research frequently relies on data from similar formulations.

Research on Septicemia and Hospital-Acquired Infections

Studies relevant to septicemia (blood infection) often involve retrospective analyses and comparative research, exploring patterns of use in high-risk hospital settings. This research examined outcomes related to physiological strain, such as mortality rates and specific adverse events, in adult patients with severe infections. This research was studied for use in patients facing Gram-negative infections and those with underlying conditions like renal impairment. Findings describe patterns observed in the studies related to how symptoms evolved and outcomes related to physiological strain or stress among these specific cohorts.

Evidence for Use in Respiratory and Intra-abdominal Infections

Research has explored the use of the combination in patients facing severe infections in the lungs (lower respiratory tract) and the abdomen. For abdominal infections, there have been some randomized controlled trials (RCTs) conducted, and studies explored the optimal duration of antibiotic treatment after surgical intervention. Researchers monitored outcomes such as measured changes in clinical signs and symptoms and studies monitored microbiological outcomes.

For severe respiratory infections, research focused on outcomes related to physical discomfort, such as fever and cough, and how patients' lab values evolved over time. These studies were observed in populations including the elderly and those classified with severe LRTI. While some research describes measured changes during the study period, the evidence quality varies across studies, and many rely on short-term follow-up durations.

Key Studies & References

  1. Cefoperazone + sulbactam versus cefotaxime + sulbactam combination therapy for the treatment of complicated urinary tract
  2. Sulbactam/Cefoperazone 1:1 and 1:2 - MAGNEX®/MAGNEX® FORTE Injection (Prescribing Information/Labeling)

Frequently Asked Questions (FAQ)

Common questions about Grct (FAQ)

Q: What should I know about taking Grct long-term?

For treatments classified in regulatory documents as extended therapy, official guidance advises that periodic checks of organ systems are appropriate. This may involve monitoring the function of the kidney (renal), liver (hepatic), and the blood-forming (hematopoietic) systems, as described in official documents.

Q: Are there any common foods or drinks that interact with Grct?

Official labeling describes a restriction on consuming alcohol (ethanol) during treatment and for a specified period, such as 72 hours, following the last dose. This is due to the potential for a specific disulfiram-like reaction. Official safety information does not generally note restrictions related to common foods.

Q: Will Grct impact my ability to drive or operate machinery?

Regulatory documents list potential adverse effects such as dizziness and headache. Official documentation describes that the effects of any medicine may impact a person's ability to drive or safely operate machinery.

Q: Are there any serious side effects of Grct that I should be aware of?

Official safety information includes warnings about serious events such as severe allergic (hypersensitivity) reactions, which can sometimes be fatal. There is also a potential risk for hemorrhage (bleeding) and rare, severe Severe Cutaneous Adverse Reactions (SCARs).

Q: What kind of monitoring (e.g., blood tests) might be needed while on Grct?

During extended use, official guidance includes the advice to check the function of the kidney, liver, and blood-forming systems. Regulatory documents state that monitoring of prothrombin time (a blood clotting test) may also be necessary for patients with an increased bleeding risk.

Q: What happens when I stop taking Grct?

Most potential effects occur during treatment. However, official safety documents specifically note that some effects, such as a severe form of diarrhea known as Clostridium difficile-associated diarrhea (CDAD), have been reported to occur two months or more following the completion of treatment.

Q: Is Grct considered a maintenance medicine or a temporary one?

According to official product information, the medicine is administered as a defined course of therapy. The duration of this course is described as typically lasting until the underlying bacterial infection has been resolved.

Q: Does Grct make you tired or drowsy?

Official safety information does not commonly list tiredness or drowsiness as frequent adverse reactions. However, some official documents note that effects such as dizziness have been reported.

Q: Can Grct affect my mood or mental health?

Effects on the Central Nervous System (CNS) are possible, though uncommon. Regulatory documents list less frequent adverse effects such as confusion in the official safety profile.

Q: Is it common to feel [specific mild symptom, e.g., slightly dizzy] after starting Grct?

The most common adverse reaction noted in regulatory documents is diarrhea. Other effects, such as dizziness, are reported in official safety documents, but are not listed among the most frequent effects.

Q: What is the recommended period of time to use Grct for?

The duration of use is defined as a course of therapy in official labeling. This course is described as typically lasting until the specific bacterial infection has been resolved.

Q: What is the typical time frame for side effects from Grct to appear?

Most adverse reactions occur during the course of therapy. However, regulatory documents specifically note that some delayed effects, such as a severe form of diarrhea known as CDAD, can occur two months or more after the medicine has been discontinued.

Q: Why is Grct sometimes given with other medications?

The medicine may be used with other antibiotics when treating complex infections, such as when a co-infection is suspected. For example, regulatory guidance describes that appropriate anti-chlamydial coverage is often included when C. trachomatis is present, as Grct is not active against all types of organisms.

Q: Is it okay to take vitamins or supplements while using Grct?

Regulatory documents note that the medicine can interfere with Vitamin K-dependent clotting factors. Official guidance describes that exogenous Vitamin K (a supplement) is sometimes administered in certain patients, particularly those with poor nutritional status or a bleeding risk.

Q: Can Grct cause changes to my skin or hair?

Regulatory documents note the potential for skin reactions, including common effects like rash and hives (urticaria), and rare, severe reactions such as Stevens-Johnson Syndrome (SJS). No effects on hair are typically reported in the official safety profile.

Q: How long does Grct stay in my system after I stop taking it?

Factual information from pharmacokinetic studies indicates that the mean half-life of the Cefoperazone component (how long it takes for half the drug to be eliminated) is approximately 1.7 to 2.0 hours.

Q: Are there specific symptoms that require immediate medical attention while using Grct?

Official labeling lists symptoms of serious allergic reactions (e.g., swelling of the face or throat, trouble breathing) and symptoms of severe skin reactions (e.g., blistering, red lesions, fever) that official documents recommend are immediately reviewed by a medical professional.

Q: Does research show Grct has better outcomes for certain patient groups?

Studies have explored the effectiveness of the combination by focusing on specific patient groups and cohorts. This has included research on patients with hepatic and renal impairment, the elderly, and those facing specific conditions like septicemia.

Q: Is Grct used for managing chronic pain?

The approved purpose of this medicine, as defined in regulatory labeling, is for the treatment of susceptible bacterial infections. It is not indicated or defined in official documents for the management of chronic pain.

Q: Why do I need a prescription for Grct?

The medicine is classified as a prescription-only drug due to its specific formulation (a powder for injection), its specialized administration method (parenteral injection), and its use in treating serious bacterial infections.

Q: What is the difference between the brand name and generic Grct?

The brand name and generic versions contain the same active medicinal ingredients (Cefoperazone and Tazobactam/Sulbactam). Official government standards require that generic products meet strict requirements for quality and bioequivalence.

Q: Is Grct a Schedule drug (controlled substance)?

The medicine is an antibiotic combination. According to regulatory authorities, it is not classified as a controlled substance under the schedules defined by the relevant government acts.

Q: Are there any age restrictions for taking Grct?

Official labeling states that use is not recommended in neonates (newborns) or preterm infants due to specific safety concerns. The use in older children (pediatric patients) is defined for certain bacterial infections based on body weight.

Q: How effective is Grct according to clinical trial data?

Studies have explored the effectiveness of the combination by examining its activity against bacterial resistance mechanisms. Research findings describe patterns observed in studies related to measured changes in clinical signs and symptoms associated with the infection being treated.

Q: Is Grct used 'off-label' for other conditions?

The medicine is officially approved and indicated only for the treatment of susceptible bacterial infections as defined in the regulatory labeling.

Q: Can I take Grct if I have liver or kidney problems?

Official guidance describes that use requires caution and close monitoring for patients with severe hepatic (liver) disease or renal (kidney) impairment. The labeling requires that the dose be adjusted for these conditions to manage exposure to the drug components.

Q: Is Grct approved for use in children?

Pediatric patients are eligible for use under specific indications. However, it is not recommended for use in neonates or premature infants due to specific documented safety concerns in official labeling.

Q: What are the known long-term side effects of Grct based on studies?

Regulatory overviews of the research state that specific, large-scale studies focused directly on long-term patient outcomes for this specific combination antibiotic are not broadly characterized in the official evidence base.

Q: What if I have an allergic reaction to Grct?

Regulatory documents state that serious hypersensitivity (allergic) reactions have occurred. Official guidance indicates that, in the event of a severe reaction, the medicine is discontinued and appropriate medical therapy initiated.

How should Grct be stored and disposed of?

How to Store and Dispose of Cefoperazone/Tazobactam (Grct)

Official regulatory guidelines determine the required storage conditions to ensure the stability of the dry powder for injection.

Detail Official Regulatory Requirement
Storage Temperature Store the unopened dry vial at controlled room temperature, typically 20 C to 25 C. Do not store above 30 C.
Protection The product must be protected from light and stored in the original, tightly closed container.
Child Safety Must be kept out of the sight and reach of children.
Disposal Rule Unused or expired medicine must be disposed of in accordance with local regulations and must not be thrown away via wastewater or household waste.

Once the dry powder is mixed, the reconstituted solution has a limited stability period that depends on the diluent used, and any unused portion must be discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Grct found in:

A-Z Index: